EUCTR2010-020398-18-DE进行中（未招募）不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas - GAMMA
Amgen Inc.0 个研究点目标入组 825 人开始时间: 2011年2月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 825
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must have histologically or cytologically confirmed metastatic
- •adenocarcinoma of the pancreas (American Joint Committee on Cancer Stage IV); ECOG score of 0 or 1; Men or women = 18 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 470
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 355
排除标准
- •Islet cell, acinar cell carcinoma, non-adenocarcinoma, (eg, lymphoma,
- •sarcoma, etc), adenocarcinoma originated from biliary tree or cystadenocarcinoma; currently treated or previously treated with biologic, small molecule, immunotherapy, chemotherapy (eg, gemcitabine), radiotherapy, chemoradiotherapy or other agents for pancreatic cancer.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas - GAMMAmetastatic adenocarcinoma of the pancreasMedDRA version: 12.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableEUCTR2010-020398-18-SIAmgen Inc.825
进行中（未招募）
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-ESCelgene International II Sàrl485
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with Myelofibrosis de riesgo intermedio de nivel 2 o altoPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 14.0Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001897-25-ESsanofi-aventis recherche & développement225
已完成
3 期
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn*s DiseaseNL-OMON54627Celgene International II Sàrl2
进行中（未招募）
不适用
Phase 3 Study of SAR302503 in Intermediate-2 and High risk patients with MyelofibrosisPrimary myelofibrosis, post-polycythemia vera myelofibrosis, or post- essential thrombocythemia myelofibrosisMedDRA version: 16.1Level: LLTClassification code 10018864Term: Haematopoietic neoplasm NOSSystem Organ Class: 100000004864EUCTR2011-001897-25-DEsanofi-aventis recherche & développement225